Evidence map›Paper›PMID 38950954›Full record

Observational studyThe Journal of rheumatology2024

Prevalence and Risk Factors of Postacute Sequelae of COVID-19 in Adults With Systemic Autoimmune Rheumatic Diseases.

Mayan S Teles, Janetta Brundage, Teresa Po-Yu Chiang, Jennifer L Alejo, Nicolas Henriquez, Rachel Wallwork, Lisa Christopher-Stine, Allan Massie, Dorry L Segev, Caoilfhionn M Connolly and 2 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Journal of rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Long COVID and the kidney.Nature reviews. Nephrology · 2025
    Review
  2. Article
  3. Post-acute sequela of COVID-19 infection in individuals with multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025
    Article
  4. [COVID-19 vaccines efficacy and infection features in patients with systemic sclerosis: A single-center cohort study].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mayan S TelesM.S. Teles, BS, J. Brundage, MA, T.P.Y. Chiang, MD, MPH, J.L. Alejo, MD, N. Henriquez, BA, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4897-4309
Janetta BrundageM.S. Teles, BS, J. Brundage, MA, T.P.Y. Chiang, MD, MPH, J.L. Alejo, MD, N. Henriquez, BA, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-9375-1844
Teresa Po-Yu ChiangM.S. Teles, BS, J. Brundage, MA, T.P.Y. Chiang, MD, MPH, J.L. Alejo, MD, N. Henriquez, BA, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-0601-7420
Jennifer L AlejoM.S. Teles, BS, J. Brundage, MA, T.P.Y. Chiang, MD, MPH, J.L. Alejo, MD, N. Henriquez, BA, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3137-9271
Nicolas HenriquezM.S. Teles, BS, J. Brundage, MA, T.P.Y. Chiang, MD, MPH, J.L. Alejo, MD, N. Henriquez, BA, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0001-1870-4108
Rachel WallworkR. Wallwork, MD, L. Christopher-Stine, MD, MPH, C.M. Connolly, MD, MSc, J.J. Paik, MD, MHS, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-0073-7438
Lisa Christopher-StineR. Wallwork, MD, L. Christopher-Stine, MD, MPH, C.M. Connolly, MD, MSc, J.J. Paik, MD, MHS, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-7150-7306
Allan MassieA. Massie, PhD, D.L. Segev, MD, PhD, Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA.ORCID 0000-0002-5288-5125
Dorry L SegevA. Massie, PhD, D.L. Segev, MD, PhD, Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA.ORCID 0000-0002-1924-4801
Caoilfhionn M ConnollyR. Wallwork, MD, L. Christopher-Stine, MD, MPH, C.M. Connolly, MD, MSc, J.J. Paik, MD, MHS, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-1898-3530
Julie J PaikR. Wallwork, MD, L. Christopher-Stine, MD, MPH, C.M. Connolly, MD, MSc, J.J. Paik, MD, MHS, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-8436-1601
William A WerbelW.A. Werbel, MD, PhD, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; wwerbel1@jhmi.edu.ORCID 0000-0003-2943-5895

Funding

HOPE in Action: A Clinical Trial of HIV-to-HIV Liver TransplantationU01AI138897 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Christine Marie Durand, DORRY L. SEGEV · 2018 to 2026
$25.5M
HOPE in Action: A clinical trial of HIV-to-HIV deceased donor kidney transplantationU01AI134591 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DURAND, CHRISTINE MARIE, SEGEV, DORRY L. · 2017 to 2021
$11.0M
Continuous allocation score design for guaranteeing equity and reducing discards in kidney and liver transplantationR01DK132395 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Allan B Massie · 2023 to 2026
$2.7M
Patient Oriented Research in Solid Organ TransplantationK24AI144954 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SEGEV, DORRY L. · 2020 to 2024
$956k
The Landscape of Serious Infections following Kidney Transplantation in People Living with HIVK23AI157893 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WERBEL, WILLIAM · 2021 to 2025
$847k
Skeletal Myopathy in Systemic Sclerosis: Devising a Classification Schema Predictive of OutcomesK23AR073927 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PAIK, JULIE JISUN · 2020 to 2024
$787k
NIAID NIH HHS K23 AI157893NIAID NIH HHS K24 AI144954NIAID NIH HHS U01 AI134591NIAID NIH HHS U01 AI138897NIAMS NIH HHS K23 AR073927NIDDK NIH HHS R01 DK132395
6 · The paper itself

Abstract

objectiveIncidence and manifestations of postacute sequelae of coronavirus disease 2019 (PASC) are poorly defined among immunosuppressed populations. We reported, phenotyped, and assessed risk factors for PASC in adults with systemic autoimmune diseases.

methodsPersons aged ≥ 18 years with systemic autoimmune diseases were recruited into a national, prospective observational cohort of SARS-CoV-2 vaccination and infection between December 2020 and April 2021. Serial surveys assessed vaccination status, SARS-CoV-2 infection incidence, and disease flares. Participants reporting SARS-CoV-2 infection received a questionnaire assessing symptom duration, severity, and quality of life (QOL) effect; PASC was defined as ≥ 1 symptom persisting for > 12 weeks. PASC syndromes were mapped by overlapping symptom domains. Characteristics were compared between participants who did vs did not report PASC.

resultsAmong 1615 participants, 590 (36.5%) reported SARS-CoV-2 infection and were sent PASC surveys, 299 (50.7%) of whom responded > 12 weeks following the reported infection. Respondents were 91.6% female, 91.2% White, median (IQR) age was 48 (40-60) years with median (IQR) 3 (2-3) vaccine doses at time of first infection. Common diagnoses included inflammatory arthritis (38.5%) and inflammatory bowel disease (14.4%). Eighty-nine of 299 (29.8%) reported PASC, with the most reported symptom domain being neurological/psychological (83.1%); 84% reported an effect on QOL. Participants with PASC reported lower number of preceding vaccines (median [IQR] 2 [2-3] vs 3 [2-3];

conclusionIn a large, real-world cohort, 29.8% of persons with systemic autoimmune disease reported PASC, often affecting QOL. Preceding vaccination may reduce PASC, whereas multiple infections may increase risk, supporting ongoing booster vaccine campaigns and efforts to limit breakthrough infections.

Indexed as

Autoimmune DiseasesCOVID-19Rheumatic DiseasesSARS-CoV-2AdultAgedFemaleHumansImmunocompromised HostMaleMiddle AgedPost-Acute COVID-19 SyndromePrevalenceProspective StudiesQuality of LifeRisk Factorsautoimmune diseasesCOVID-19 vaccinationpostacute COVID-19 syndromerheumatic diseasesSARS-CoV-2

Identifiers

PMID38950954
PMCPMC11397179

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.